Loading...Loading...The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practice will meet this week to consider and recommend who should get respiratory syncytial virus (RSV), influenza, and COVID-19 vaccines.In the presentation slides to the U.S. agency, Moderna Inc MRNA shared safety set data, with a cut-off date of March 8, 2024, based on the median of 18.8 months of follow-up.The data showed that vaccine efficacy fell to around 50% after 18 months on participants aged 60 ...

Moderna TodayMRNAModerna$140.03 -5.20 (-3.58%) 52-Week Range$62.55▼$170.47Price Target$129.02Add to WatchlistBiotechnology firm Moderna Inc. NASDAQ: MNRA made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA (mRNA) technology for the development of innovative treatments. The company continues expanding its treatments for various diseases and illnesses, including cardiovascular disease, cancer, and other rare diseases. Moderna has been working on persona ...

文章核心观点 - 公司正在努力将业务拓展到新冠疫苗以外的领域,最近获批了呼吸道合胞病毒(RSV)疫苗,并宣布了新冠/流感联合疫苗的积极临床试验结果[1][2][7] - 公司的mRNA技术平台在过去几年里取得了重要进展,不仅成功开发了新冠疫苗,还有其他多个候选药物处于临床试验阶段,包括巨细胞病毒疫苗和个体化癌症疫苗[8][9][10] - 尽管公司股价在过去几年有所下跌,但凭借丰富的管线和创新的技术平台,公司未来前景看好,值得投资者关注[6][11] 关键要点总结 公司业务拓展 - 公司正在努力将业务拓展到新冠疫苗以外的领域,最近获批了呼吸道合胞病毒(RSV)疫苗[7] - 公司开发了新冠/流感联合疫苗,在临床三期试验中取得积极结果,有望在未来一年内获批[3][4][5] 公司技术平台 - 公司的mRNA技术平台在过去几年里取得了重要进展,不仅成功开发了新冠疫苗,还有其他多个候选药物处于临床试验阶段[9][10] - 公司正在开发巨细胞病毒疫苗和个体化癌症疫苗等其他重要产品[8] 公司前景展望 - 尽管公司股价在过去几年有所下跌,但凭借丰富的管线和创新的技术平台,公司未来前景看好,值得投资者关注[6][11]

文章核心观点 - Moderna公司宣布其新一代冰箱稳定的COVID-19疫苗mRNA-1283在12岁及以上人群中的III期临床试验取得积极结果 [1][2][3] - mRNA-1283与Moderna之前批准的针对Omicron BA.4/BA.5的双价疫苗mRNA-1273.222相比,具有更高的疫苗有效性 [2][3] - mRNA-1283能够产生更强的针对Omicron BA.4/BA.5和原始毒株的免疫应答,并具有更长的保质期和储存优势 [3] - Moderna还报告了其将mRNA-1283与流感疫苗mRNA-1010结合的mRNA-1083在50岁及以上人群中的III期临床试验取得积极结果 [4][5] - 如果获批,这种组合疫苗有助于提高疫苗接种率和方便性,从而降低COVID-19住院率 [5][6] - Moderna还计划今年晚些时候向FDA提交mRNA-1010作为独立流感疫苗的申请,该疫苗在临床试验中显示优于GSK和赛诺菲的现有流感疫苗 [7] - 这些新产品的上市是Moderna到2028年推出15种新产品的计划的一部分 [8] - 与竞争对手Novavax和辉瑞/BioNTech相比,Moderna是首家报告COVID-19/流感组合疫苗III期试验阳性数据的公司 [9][10][11]

Moderna (MRNA) announced positive results from an ongoing late-stage study evaluating mRNA-1083, its investigational mRNA-based combination vaccine against influenza and COVID-19, in older adults (50 years and older).The phase III study met its primary endpoints, showing that mRNA-1083 elicited higher immune responses against influenza and COVID-19 compared with licensed standalone influenza and COVID-19 vaccines.These results are based on a study that evaluated the vaccine in about 8,000 adults divided int ...

On Friday, the U.S. Federal Drug Administration (FDA) okayed the launch of updated vaccines as part of the 2024-2025 campaign against new Covid strains. Drug manufacturers have been waiting on approval from the agency, whose decision-making was complicated by the fact that the virus keeps mutating. FDA settled on targeting JN.1 — the variant responsible for most Covid cases of early this year. A vaccine targeting JN. 1 should offer broader protection against its offshoots KP.2, KP.3 and others that may pop ...

Moderna (MRNA) closed the most recent trading day at $148.59, moving -1.6% from the previous trading session. This change lagged the S&P 500's 0.26% gain on the day. On the other hand, the Dow registered a gain of 0.18%, and the technology-centric Nasdaq increased by 0.35%.Shares of the biotechnology company have appreciated by 28.73% over the course of the past month, outperforming the Medical sector's gain of 3.06% and the S&P 500's gain of 3.25%.Market participants will be closely following the financial ...

会议主要讨论的核心内容 - 公司有超过40个在研项目,在管理研发投入方面的策略是根据4大治疗领域(呼吸疫苗、其他病毒疫苗、肿瘤、罕见病)来优先推进5-10个药物 [4][5][6][7] - 公司与Blackstone Life Sciences合作,通过项目融资的方式来支持流感疫苗项目的开发,以腾出资金投入其他项目 [9][10][11][12] - 公司正在关注禽流感病毒的演化,并与政府就疫苗开发和供应进行讨论 [14][15][16][17][18][19][20][21] - 公司发布了流感-新冠联合疫苗三期临床数据,显示该疫苗在流感和新冠两个方面都优于市场领先产品,有望提高接种率并带来经济效益 [23][24][25][26][27][28][31] 问答环节重要的提问和回答 问题1 **Salveen Richter 提问** 公司如何看待mRNA疫苗与传统蛋白疫苗在流感疫苗市场的竞争 [33] **Stephen Hoge 回答** mRNA疫苗已有大量安全性数据,随着时间推移,人们会更关注疫苗的推荐和好处,而不是疫苗技术本身 [34][35][36] 问题2 **Salveen Richter 提问** 公司在欧盟新冠疫苗招标中的进展如何 [37][38][39][40][41] **Stephen Hoge 回答** 公司正在与欧盟就今年供应新冠疫苗的事宜进行谈判,具体结果还需等待欧盟的决定 [38][39][40] 问题3 **Salveen Richter 提问** 公司RSV疫苗的上市情况如何,与竞争对手相比的优势在哪里 [44][45][46][47][48][49][50][51][52][53][54][55][56][57] **Stephen Hoge 回答** 公司RSV疫苗已获批上市,在疗效和安全性方面优于竞争对手,正在积极与各方进行商务谈判,希望在未来几年内获得较大市场份额 [44][45][46][47][48][49][50][51][52][53][54][55][56][57]

Moderna, Inc. (MRNA) announced that it has submitted an application to the FDA seeking approval of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1, the latest variant of the novel virus responsible for the 2020 pandemic. The regulatory filing is based on guidance from the FDA last week, whereby the regulatory body advised eminent vaccine manufacturers like Moderna, Novavax (NVAX) and Pfizer (PFE) to update their respective COVID-19 vaccines to a monovalent (single strain) JN.1 compositio ...

ToplineModerna on Monday said its combination COVID-19 and flu shot elicits a stronger immune response against both viruses than licensed vaccines on the market, promising findings for the mRNA company as it works to diversify into areas like influenza and cancer amid diminishing demand for coronavirus shots.Moderna has announced promising data on a combination COVID-flu vaccine. Getty Images Key FactsModerna’s combination shot is made up of components from two of Moderna’s other experimental shots for seas ...